{"entity":{"id":"2029","kind":"year","name":"2029 in oncology","aka":["2029"],"tldr":"Everything OnCo dates to 2029: 10 entries, 10 expected dates. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.","summary":"10 dated entries in OnCo fall in 2029: 10 expected dates.\n\nOf those, 9 to the day and 1 to the month. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.\n\nEverything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.","asOf":"2026-09-25","links":[],"tags":[],"related":["2028","2030"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Generated from every dated field in the corpus, not written by hand. The groups and the fields behind them are listed in src/lib/year-groups.ts; the reader is src/lib/years.ts."],"year":2029,"events":[{"group":"expected","date":"2029-01-02","precision":"day","title":"ARTEMIDE-Biliary01 primary completion: adjuvant rilvegostomig plus chemotherapy after resection of biliary tract cancer (760 participants)","note":"Watch item on the Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials.","from":"gallbladder-cancer-roadmap","refs":["nct06109779","rilvegostomig"]},{"group":"expected","date":"2029-01-31","precision":"day","title":"Vanguard study primary completion: the NCI's randomised feasibility trial of multi-cancer detection tests in 24,000 people","note":"Watch item on the ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment.","from":"ctdna-tests","refs":["vanguard-study","nci"]},{"group":"expected","date":"2029-03","precision":"month","title":"RASolute 309 primary completion: zoldonrasib plus daraxonrasib versus gemcitabine and nab-paclitaxel, first line KRAS G12D metastatic disease (400 estimated par...","note":"Watch item on the Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveill...","from":"pancreatic-roadmap","refs":["nct07805954","zoldonrasib","daraxonrasib","g12d-plus-pan-ras"]},{"group":"expected","date":"2029-03-10","precision":"day","title":"CIRCULATE-US (NRG-GI008) primary completion: adjuvant chemotherapy directed by residual disease on circulating tumour DNA (1,912 estimated participants; recruit...","note":"Watch item on the Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherap...","from":"colorectal-roadmap","refs":["mrd-testing","signatera","ctdna","idea-crc-ctdna-de-escalation-beyond-stage-ii"]},{"group":"expected","date":"2029-03-10","precision":"day","title":"CIRCULATE-US primary completion: ctDNA-guided escalation and de-escalation of adjuvant chemotherapy in stage III colon cancer","note":"Watch item on the ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment.","from":"ctdna-tests","refs":["circulate-us","signatera"]},{"group":"expected","date":"2029-03-19","precision":"day","title":"Perioperative dostarlimab in untreated T4N0 or stage III mismatch repair-deficient resectable colon cancer, primary completion (892 estimated participants; phas...","note":"Watch item on the Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherap...","from":"colorectal-roadmap","refs":["dostarlimab","niche-2","msi-high-colorectal","organ-preservation"]},{"group":"expected","date":"2029-05-10","precision":"day","title":"RASolute 304 primary completion: adjuvant daraxonrasib in resected pancreatic ductal adenocarcinoma (500 estimated participants; recruiting)","note":"Watch item on the Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveill...","from":"pancreatic-roadmap","refs":["nct07252232","daraxonrasib","prodige-24"]},{"group":"expected","date":"2029-05-28","precision":"day","title":"OlympiA study completion on the registry (adjuvant olaparib; primary completion 27 March 2020, actual; six-year update published 2026)","note":"Watch item on the Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease proble...","from":"tnbc-roadmap","refs":["olympia","olaparib","paper-olympia-6-year-update-ann-oncol-2026"]},{"group":"expected","date":"2029-07-31","precision":"day","title":"TRACC primary completion: 1,000 people with early colorectal cancer followed by ctDNA","note":"Watch item on the ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment.","from":"ctdna-tests","refs":["tracc"]},{"group":"expected","date":"2029-09-30","precision":"day","title":"WISDOM (Women Informed to Screen Depending on Measures of Risk): primary completion","note":"Estimated primary completion date on ClinicalTrials.gov.","from":"wisdom-trial","refs":[]}]},"route":"/years/2029/","neighbours":{"year":[{"id":"2028","kind":"year","name":"2028 in oncology","route":"/years/2028/"},{"id":"2030","kind":"year","name":"2030 in oncology","route":"/years/2030/"}]}}